These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

579 related articles for article (PubMed ID: 31181727)

  • 1.
    Fararjeh AS; Liu YN
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2.
    Tsai YC; Chen WY; Abou-Kheir W; Zeng T; Yin JJ; Bahmad H; Lee YC; Liu YN
    Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1717-1727. PubMed ID: 29477409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
    Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
    Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.
    Shafran JS; Andrieu GP; Györffy B; Denis GV
    Mol Cancer Res; 2019 Aug; 17(8):1627-1638. PubMed ID: 31110158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
    Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
    Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
    [No Abstract]   [Full Text] [Related]  

  • 7. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46.
    Liu YN; Niu S; Chen WY; Zhang Q; Tao Y; Chen WH; Jiang KC; Chen X; Shi H; Liu A; Li J; Li Y; Lee YC; Zhang X; Huang J
    Clin Cancer Res; 2019 Jul; 25(13):4128-4140. PubMed ID: 30962287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
    Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C
    Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
    Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH
    Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer.
    Chen WY; Tsai YC; Yeh HL; Suau F; Jiang KC; Shao AN; Huang J; Liu YN
    Sci Signal; 2017 Aug; 10(492):. PubMed ID: 28811384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
    Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
    Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
    Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer.
    Perner S; Cronauer MV; Schrader AJ; Klocker H; Culig Z; Baniahmad A
    Oncotarget; 2015 Nov; 6(34):35542-55. PubMed ID: 26325261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
    Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development.
    He H; Hao J; Dong X; Wang Y; Xue H; Qu S; Choi SYC; Ci X; Wang Y; Wu R; Shi M; Zhao X; Collins C; Lin D; Wang Y
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):775-785. PubMed ID: 33568749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
    Cai Z; Chen W; Zhang J; Li H
    Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
    McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
    Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets.
    Ramalingam S; Ramamurthy VP; Njar VCO
    J Steroid Biochem Mol Biol; 2017 Feb; 166():16-27. PubMed ID: 27481707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.